| 1 |
Engineered antibody Fc variants with enhanced effector function
Greg A. Lazar, Wei Dang, Sher Karki et al. · Proceedings of the National Academy of Sciences
Open access |
6 Mar 2006 |
804 |
| 2 |
Enhanced antibody half-life improves in vivo activity
Jonathan Zalevsky, Aaron K. Chamberlain, Holly M. Horton et al. · Nature Biotechnology
Open access |
17 Jan 2010 |
664 |
| 3 |
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
Matthew T. Nguyen, Hiroaki Satoh, Svetlana Favelyukis et al. · Journal of Biological Chemistry
Open access |
6 Aug 2005 |
405 |
| 4 |
Characterizing biological products and assessing comparability following manufacturing changes
Arthur J. Chirino, Anthony R. Mire‐Sluis · Nature Biotechnology
|
Nov 2004 |
364 |
| 5 |
Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease
Melissa K. McCoy, Terina N. Martinez, Kelly A. Ruhn et al. · Journal of Neuroscience
Open access |
13 Sep 2006 |
362 |
| 6 |
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
John O. Richards, Sher Karki, Greg A. Lazar et al. · Molecular Cancer Therapeutics
|
Aug 2008 |
311 |
| 7 |
Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
Holly M. Horton, Matthew J. Bernett, Erik Pong et al. · Cancer Research
|
30 Sep 2008 |
272 |
| 8 |
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
Gregory L. Moore, Hsing Chen, Sher Karki et al. · mAbs
Open access |
Mar 2010 |
264 |
| 9 |
Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants
Paul M. Steed et al. · Science
|
25 Sep 2003 |
261 |
| 10 |
Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination
Roberta Brambilla, Jessica Jopek Ashbaugh, Roberta Magliozzi et al. · Brain
Open access |
29 Aug 2011 |
215 |
| 11 |
Rational design and engineering of therapeutic proteins
Shannon A. Marshall, Greg A. Lazar, Arthur J. Chirino et al. · Drug Discovery Today
|
Mar 2003 |
204 |
| 12 |
Minimizing the immunogenicity of protein therapeutics
Arthur J. Chirino, Marylouise Ary, Shannon A. Marshall · Drug Discovery Today
|
2004 |
178 |
| 13 |
Oligodendroglial TNFR2 Mediates Membrane TNF-Dependent Repair in Experimental Autoimmune Encephalomyelitis by Promoting Oligodendrocyte Differentiation and Remyelination
Pernille M. Madsen, Dario Motti, Shaffiat Karmally et al. · Journal of Neuroscience
Open access |
4 May 2016 |
162 |
| 14 |
Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection
Jonathan Zalevsky, Thomas Sécher, Sergei A. Ezhevsky et al. · The Journal of Immunology
|
Aug 2007 |
161 |
| 15 |
Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies
Seung Y. Chu, Igor Voštiar, Sher Karki et al. · Molecular Immunology
|
13 Aug 2008 |
158 |
| 16 |
Antibody-Mediated Coengagement of FcγRIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus
Holly M. Horton, Seung Y. Chu, Elizabeth Ortiz et al. · The Journal of Immunology
|
Mar 2011 |
145 |
| 17 |
Soluble TNF Mediates the Transition from Pulmonary Inflammation to Fibrosis
Nikos Oikonomou, Vaggelis Harokopos, Jonathan Zalevsky et al. · PLoS ONE
Open access |
26 Dec 2006 |
136 |
| 18 |
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective
John R. Desjarlais, Greg A. Lazar, Eugene A. Zhukovsky et al. · Drug Discovery Today
|
Nov 2007 |
134 |
| 19 |
Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
Christina L. Zuch de Zafra, Flordeliza Fajardo, Wendy W. H. Zhong et al. · Clinical Cancer Research
|
28 Mar 2019 |
133 |
| 20 |
Cation−π Interactions: An Energy Decomposition Analysis and Its Implication in δ-Opioid Receptor−Ligand Binding
Yirong Mo, Govindan Subramanian, Jiali Gao et al. · Journal of the American Chemical Society
|
5 Apr 2002 |
132 |
| 21 |
Combining computational and experimental screening for rapid optimization of protein properties
Robert J. Hayes, Jörg Bentzien, Marylouise Ary et al. · Proceedings of the National Academy of Sciences
Open access |
21 Nov 2002 |
130 |
| 22 |
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody
Farrukh Tauseef Awan, Rosa Lapalombella, Rossana Trotta et al. · Blood
Open access |
3 Dec 2009 |
130 |
| 23 |
Hippocampal TNFα Signaling Contributes to Seizure Generation in an Infection-Induced Mouse Model of Limbic Epilepsy
Dipan C. Patel, Glenna J. Wallis, E. Jill Dahle et al. · eNeuro
Open access |
Mar 2017 |
112 |
| 24 |
Degrading chloroplast mRNA: the role of polyadenylation
Robert J. Hayes, Jörg Kudla, Wilhelm Gruissem · Trends in Biochemical Sciences
Review |
May 1999 |
112 |
| 25 |
Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia
Maria Karamita, Christopher J. Barnum, Wiebke Möbius et al. · JCI Insight
Open access |
19 Apr 2017 |
111 |
| 26 |
A molecular immunology approach to antibody humanization and functional optimization
Greg A. Lazar, John R. Desjarlais, Jonathan M. Jacinto et al. · Molecular Immunology
|
2 Nov 2006 |
110 |
| 27 |
Thoroughly sampling sequence space: Large‐scale protein design of structural ensembles
Stefan Larson, Jeremy L. England, John R. Desjarlais et al. · Protein Science
Open access |
20 Nov 2002 |
109 |
| 28 |
Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia
Bettina Hjelm Clausen, Matilda Degn, Nellie Anne Martin et al. · Journal of Neuroinflammation
Open access |
Dec 2014 |
106 |
| 29 |
A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens
Gregory L. Moore, Cristina Bautista, Erik Pong et al. · mAbs
Open access |
Nov 2011 |
105 |
| 30 |
The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates
Jonathan Zalevsky, Irene Leung, Sher Karki et al. · Blood
|
25 Dec 2008 |
101 |
| 31 |
Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicity
Maria D.F.S. Barbosa, Jost Vielmetter, Seung Y. Chu et al. · Clinical Immunology
|
3 Nov 2005 |
100 |
| 32 |
Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-κB
Era Taoufik, Vivian Tseveleki, Seung Y. Chu et al. · Brain
|
29 Aug 2011 |
95 |
| 33 |
Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody
Seung Y. Chu, Holly M. Horton, Erik Pong et al. · Journal of Allergy and Clinical Immunology
|
16 Jan 2012 |
95 |
| 34 |
DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3
Rahul S. Bhansali et al. · Journal of Clinical Investigation
Open access |
3 Jan 2021 |
92 |
| 35 |
The TNF superfamily in 2009: new pathways, new indications, and new drugs
Malu Gámez Tansey, David E. Szymkowski · Drug Discovery Today
|
17 Oct 2009 |
89 |
| 36 |
Transmembrane TNF‐α is sufficient for articular inflammation and hypernociception in a mouse model of gout
Flávio Almeida Amaral, Leandro F.S. Bastos, Thiago Henrique Oliveira et al. · European Journal of Immunology
Open access |
9 Oct 2015 |
82 |
| 37 |
Computational stabilization of human growth hormone
Anton V. Filikov, Robert J. Hayes, Peizhi Luo et al. · Protein Science
Open access |
Jun 2002 |
77 |
| 38 |
Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
Holly M. Horton, Matthew J. Bernett, Matthias Peipp et al. · Blood
Open access |
9 Jul 2010 |
74 |
| 39 |
Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice
Hans Gram Novrup, Valerie C. Bracchi-Ricard, Ditte Gry Ellman et al. · Journal of Neuroinflammation
Open access |
9 Sep 2014 |
73 |
| 40 |
A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats
Gregory L. Moore, Matthew J. Bernett, Rumana Rashid et al. · Methods
Open access |
23 Oct 2018 |
72 |
| 41 |
Harnessing Fc receptor biology in the design of therapeutic antibodies
Peter Sondermann, David E. Szymkowski · Current Opinion in Immunology
Review |
30 Mar 2016 |
72 |
| 42 |
Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial
Cory A. Perugino, Zachary Scott Wallace, Debra Jeske Zack et al. · The Lancet Rheumatology
|
24 Jul 2023 |
70 |
| 43 |
Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study
Farhad Ravandi, Asad Bashey, Wendy Stock et al. · Blood
|
4 Nov 2020 |
70 |
| 44 |
Redirected T Cell Cytotoxicity in Cancer Therapy
Raphael Clynes, John R. Desjarlais · Annual Review of Medicine
Review |
31 Oct 2018 |
70 |
| 45 |
Dissection of specific binding of HIV-1 Gag to the 'packaging signal' in viral RNA
Mauricio Comas‐García, Siddhartha AK Datta, Laura E. Baker et al. · eLife
Open access |
20 Jul 2017 |
69 |
| 46 |
Neutralization of Membrane TNF, but Not Soluble TNF, Is Crucial for the Treatment of Experimental Colitis
Clémentine Perrier, Gert D. Hertogh, Jonathan Cremer et al. · Inflammatory Bowel Diseases
Open access |
30 May 2012 |
68 |
| 47 |
Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15
Lazar N. Vujanovic, David E. Szymkowski, Sean M. Alber et al. · Blood
Open access |
30 Apr 2010 |
67 |
| 48 |
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind , Randomized, Placebo‐Controlled , Phase 2 Trial
Joan T. Merrill, Joel M. Guthridge, Miles C. Smith et al. · Arthritis & Rheumatology
|
17 Jul 2023 |
66 |
| 49 |
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL
Jennifer Ann Woyach, Farrukh Tauseef Awan, Ian W. Flinn et al. · Blood
Open access |
10 Oct 2014 |
66 |
| 50 |
Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor
Seung Y. Chu, Karen C. Yeter, Roshan Kotha et al. · Arthritis & Rheumatology
|
24 Dec 2013 |
63 |